Mid-market private equity firm Inflexion Private Equity Partners has launched a healthcare advisory board to help shape its investment strategy and drive value across its healthcare investments in the UK and internationally.

The board comprises:

Mukhtar Ahmed, president of Clarivate’s Science Group who has senior leadership roles with Oracle and Parexel.

Dee Athwal, a pharma and biotech advisor for more than 15 years, who is chief executive of Complement Therapeutics and previously held senior roles at Capella Bioscience and UCB.

John Beighton, chair of Rosemont Pharmaceuticals, Acino and Advanz, and a previous board member at Zentiva and chief executive of AMCo and Mercury Pharma.

Jan Egberts, chair of Viroclinics, PhotoCure, NordicNanovector and previously chief executive of OctoPlus, Agendia, chair of Mölnlycke Healthcare and member of the global executive board of J&J Medical.

Jane Griffiths, non-executive director at Johnson Matthew and BAE Systems, chair of Redx Pharma, who held former leadership roles at Janssen and as global head of Actelion. 

Steve Kent, chairman of Phlexglobal, 4ways and Pharmaspectra, and the former chair of CRF Health, and a board member at Parexel.

Rob Scott, formerly chief medical officer and head of development at Abbvie, who has held senior roles at Amgen and Pfizer.

Charles Woler, chair and non-executive at various life science businesses in Europe and the US, and a former chief executive of Roche France and chief executive of Cadus Pharmaceuticals.

Inflexion has a team of 11 professionals focused on healthcare investing in the UK and across Europe and has a number of healthcare companies in its portfolio including Rosemont Pharmaceuticals, CNX Therapeutics, PharmaSpectra and ELCG. 

Simon Turner, managing partner at Inflexion, said: “Healthcare is one of our core areas of sector focus since inception, and the last two years have cast a spotlight on its importance globally. We are privileged to work with some of the leading innovators in this space, through our portfolio and our wider network, and are delighted to formalise many of these relationships through this advisory board.”

Funds advised by Inflexion Private Equity Partners have funds under management of around £5.4 billion.